T cell modifying compounds and uses thereof
AssigneeSangamo Therapeutics, Inc.
InventorsPhilip D. Gregory, Michael C. Holmes
Life of this patent
Estimating the term…
Abstract
Methods and compositions for modifying T-cells in which PD1 and/or CTLA-4 is repressed and/or inactivated using fusion proteins such as artificial transcription factors and nucleases.
Claims28
1-24. (canceled)
A genetically modified T-cell that expresses a chimeric antigen receptor (CAR), wherein an exogenous sequence encoding a CAR is integrated into the genome of the T-cell using one or more nucleases, and wherein expression of at least one endogenous immunological checkpoint gene is repressed in the T-cell.
The method of claim 24, wherein the at least one additional transgene encodes a TAA-specific T-cell receptor (TCR).
Dependencies are inferred from the claim text.